News & Updates

Add-on tacrolimus a viable option for RA patients with insufficient abatacept response

25 Nov 2019

Use of tacrolimus appears to be safe and effective in the management of rheumatoid arthritis (RA) patients with inadequate response to abatacept, as shown in a recent study.

Add-on tacrolimus a viable option for RA patients with insufficient abatacept response

25 Nov 2019

Drug adherence low in pregnant women with RA

24 Nov 2019

Women with rheumatoid arthritis (RA) appear to have low utilization of medications safe to take during pregnancy, commonly discontinuing their medications in the first trimester, a recent study has found.

Drug adherence low in pregnant women with RA

24 Nov 2019

Opioid exposure negatively affects early pain response in older venlafaxine-treated patients

21 Nov 2019

Among older patients with chronic low back pain and depression who are treated with venlafaxine, exposure to opioids is associated with reduced likelihood of achieving early pain response but not that of attaining the combined pain/depression outcome, a study has shown.

Opioid exposure negatively affects early pain response in older venlafaxine-treated patients

21 Nov 2019

Fatigue, sleep disorder intensify pain of hip osteoarthritis

21 Nov 2019

Poor sleep quality and greater fatigue may worsen pain in individuals with symptomatic hip osteoarthritis (OA), results of a recent study have shown.

Fatigue, sleep disorder intensify pain of hip osteoarthritis

21 Nov 2019

Early-onset pamidronate therapy may reduce disease activity in chronic nonbacterial osteomyelitis

21 Nov 2019

Treatment with pamidronate appears to improve clinical and radiological disease activity in children categorized with extended chronic nonbacterial osteomyelitis (CNO), particularly after 1 year of treatment, a study has shown. However, some children present with active disease after 2 years of pamidronate use.

Early-onset pamidronate therapy may reduce disease activity in chronic nonbacterial osteomyelitis

21 Nov 2019

Filgotinib improves health-related quality of life in active PsA patients

21 Nov 2019

The oral, selective Janus kinase 1 inhibitor filgotinib confers a significant improvement in health-related quality of life in patients with active psoriatic arthritis (PsA), according to data from the phase II EQUATOR trial.

Filgotinib improves health-related quality of life in active PsA patients

21 Nov 2019

Patients with idiopathic inflammatory myopathies at high risk of acute coronary syndrome

20 Nov 2019

The risk of acute coronary syndrome (ACS) is increased in individuals with idiopathic inflammatory myopathies (IIM), especially within the first year following diagnosis, according to a recent study.

Patients with idiopathic inflammatory myopathies at high risk of acute coronary syndrome

20 Nov 2019

$Teriparatide better than risedronate for preventing fractures despite psychotropic, PPI exposure$

Teriparatide better than risedronate for preventing fractures despite psychotropic, PPI exposure

20 Nov 2019

Exposure to psychotropic drugs and proton pump inhibitors (PPIs) contributes to an increase risk of clinical and nonvertebral fractures in postmenopausal women with severe osteoporosis, according to a study. Furthermore, teriparatide confers superior benefits for reducing the risk of fractures compared with risedronate, irrespective of such an exposure.

Teriparatide better than risedronate for preventing fractures despite psychotropic, PPI exposure

20 Nov 2019

Immune checkpoint inhibitors tolerable in cancer patients with RA

19 Nov 2019 by

In cancer patients with rheumatoid arthritis (RA) treated with immune checkpoint inhibitors (ICIs), rates of immune-related adverse events (irAEs) are similar to those reported in patients without autoimmune diseases, with most symptoms being manageable.

Immune checkpoint inhibitors tolerable in cancer patients with RA

19 Nov 2019

Refining IFX doses does not facilitate sustained remission after treatment discontinuation

19 Nov 2019

A programmed treatment strategy of refining infliximab (IFX) doses based on baseline serum tumour necrosis factor α falls flat in sustaining remission rate in rheumatoid arthritis patients after 1 year of IFX discontinuation, according to the results of the multicentre randomized RRRR* trial.

Refining IFX doses does not facilitate sustained remission after treatment discontinuation

19 Nov 2019

News & Updates

Filter by Specialty:

Specialty:

Add-on tacrolimus a viable option for RA patients with insufficient abatacept response

Add-on tacrolimus a viable option for RA patients with insufficient abatacept response

Drug adherence low in pregnant women with RA

Drug adherence low in pregnant women with RA

Opioid exposure negatively affects early pain response in older venlafaxine-treated patients

Opioid exposure negatively affects early pain response in older venlafaxine-treated patients

Fatigue, sleep disorder intensify pain of hip osteoarthritis

Fatigue, sleep disorder intensify pain of hip osteoarthritis

Early-onset pamidronate therapy may reduce disease activity in chronic nonbacterial osteomyelitis

Early-onset pamidronate therapy may reduce disease activity in chronic nonbacterial osteomyelitis

Filgotinib improves health-related quality of life in active PsA patients

Filgotinib improves health-related quality of life in active PsA patients

Patients with idiopathic inflammatory myopathies at high risk of acute coronary syndrome

Patients with idiopathic inflammatory myopathies at high risk of acute coronary syndrome

Teriparatide better than risedronate for preventing fractures despite psychotropic, PPI exposure

Teriparatide better than risedronate for preventing fractures despite psychotropic, PPI exposure

Immune checkpoint inhibitors tolerable in cancer patients with RA

Immune checkpoint inhibitors tolerable in cancer patients with RA

Refining IFX doses does not facilitate sustained remission after treatment discontinuation

Refining IFX doses does not facilitate sustained remission after treatment discontinuation